Literature DB >> 17277145

Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization.

Michael Santosuosso1, Sarah McCormick, Elizabeth Roediger, Xizhong Zhang, Anna Zganiacz, Brian D Lichty, Zhou Xing.   

Abstract

Genetic immunization holds great promise for future vaccination against mucosal infectious diseases. However, parenteral genetic immunization is ineffective in control of mucosal intracellular infections, and the underlying mechanisms have remained unclear. By using a model of parenteral i.m. genetic immunization and pulmonary tuberculosis (TB), we have investigated the mechanisms that determine the failure and success of parenteral genetic immunization. We found that lack of protection from pulmonary Mycobacterium tuberculosis (M.tb) challenge by i.m. immunization with a recombinant adenovirus-vectored tuberculosis vaccine was linked to the absence of M.tb Ag-specific T cells within the airway lumen before M.tb challenge despite potent T cell activation in the systemic compartments. Furthermore, pulmonary mycobacterial challenge failed to recruit CD8 T cells into the airway lumen of i.m. immunized mice. Such defect in T cell recruitment, intra-airway CTL, and immune protection was restored by creating acute inflammation in the airway with inflammatory agonists such as virus. However, the Ag-specific T cells recruited as such were not retained in the airway lumen, resulting in a loss of protection. In comparison, airway exposure to low doses of soluble M.tb Ags not only recruited but retained Ag-specific CD8 T cells in the airway lumen over time that provided robust protection against M.tb challenge. Thus, our study reveals that mucosal protection by parenteral immunization is critically determined by T cell geography, i.e., whether Ag-specific T cells are within or outside of the mucosal lumen and presents a feasible solution to empower parenteral immunization strategies against mucosal infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277145     DOI: 10.4049/jimmunol.178.4.2387

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Influence of the tissue microenvironment on Toll-like receptor expression by CD11c+ antigen-presenting cells isolated from mucosal tissues.

Authors:  Shunsuke Takenaka; Sarah McCormick; Ekaterina Safroneeva; Zhou Xing; Jack Gauldie
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

2.  Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells.

Authors:  M Jeyanathan; S McCormick; R Lai; S Afkhami; C R Shaler; C N Horvath; D Damjanovic; A Zganiacz; N Barra; A Ashkar; M Jordana; N Aoki; Z Xing
Journal:  Mucosal Immunol       Date:  2013-10-30       Impact factor: 7.313

3.  Investigations of TB vaccine-induced mucosal protection in mice.

Authors:  Azra Blazevic; Christopher S Eickhoff; Jaime Stanley; Mark R Buller; Jill Schriewer; Eric M Kettelson; Daniel F Hoft
Journal:  Microbes Infect       Date:  2013-10-08       Impact factor: 2.700

4.  Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Authors:  Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

Review 5.  Immunological roulette: Luck or something more? Considering the connections between host and environment in TB.

Authors:  John E Pearl; Mrinal Das; Andrea M Cooper
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

6.  Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation.

Authors:  Sam Afkhami; Rocky Lai; Michael R D'agostino; Maryam Vaseghi-Shanjani; Anna Zganiacz; Yushi Yao; Mangalakumari Jeyanathan; Zhou Xing
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

7.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

Authors:  Elda Righi; Satoshi Kashiwagi; Jianping Yuan; Michael Santosuosso; Pierre Leblanc; Rachel Ingraham; Benjamin Forbes; Beth Edelblute; Brian Collette; Deyin Xing; Magdalena Kowalski; Maria Cristina Mingari; Fabrizio Vianello; Michael Birrer; Sandra Orsulic; Glenn Dranoff; Mark C Poznansky
Journal:  Cancer Res       Date:  2011-07-08       Impact factor: 12.701

8.  Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.

Authors:  Zhou Xing; Christine T McFarland; Jean-Michel Sallenave; Angelo Izzo; Jun Wang; David N McMurray
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

9.  CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

Authors:  Tara Elvang; Jan P Christensen; Rolf Billeskov; Truc Thi Kim Thanh Hoang; Peter Holst; Allan Randrup Thomsen; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

10.  Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection.

Authors:  Edward O Ronan; Lian Ni Lee; Peter C L Beverley; Elma Z Tchilian
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.